{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,25]],"date-time":"2024-02-25T00:13:34Z","timestamp":1708820014024},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,1,27]],"date-time":"2024-01-27T00:00:00Z","timestamp":1706313600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,27]],"date-time":"2024-01-27T00:00:00Z","timestamp":1706313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Chronic lymphocytic leukemia (CLL) is a disease of the elderly, often presenting comorbidities like osteoporosis and requiring, in a relevant proportion of cases, treatment with bisphosphonates (BPs). This class of drugs was shown in preclinical investigations to also possess anticancer properties<jats:italic>.<\/jats:italic> We started an in vitro study of the effects of BPs on CLL B cells activated by microenvironment-mimicking stimuli and observed that, depending on drug concentration, hormetic effects were induced on the leukemic cells. Higher doses induced cytotoxicity whereas at lower concentrations, more likely occurring in vivo, the drugs generated a protective effect from spontaneous and chemotherapy-induced apoptosis, and augmented CLL B cell activation\/proliferation. This CLL-activation effect promoted by the BPs was associated with markers of poor CLL prognosis and required the presence of bystander stromal cells. Functional experiments suggested that this phenomenon involves the release of soluble factors and is increased by cellular contact between stroma and CLL B cells. Since CLL patients often present comorbidities such as osteoporosis and considering the diverse outcomes in both CLL disease progression and CLL response to treatment among patients, illustrating this phenomenon holds potential significance in driving additional investigations.<\/jats:p>","DOI":"10.1007\/s00262-023-03588-z","type":"journal-article","created":{"date-parts":[[2024,1,27]],"date-time":"2024-01-27T11:02:21Z","timestamp":1706353341000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Unexpected chronic lymphocytic leukemia B cell activation by bisphosphonates"],"prefix":"10.1007","volume":"73","author":[{"given":"Andrea N.","family":"Mazzarello","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Gugiatti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa","family":"Cossu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadia","family":"Bertola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davide","family":"Bagnara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonia","family":"Carta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Ravera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Salvetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adalberto","family":"Ibatici","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Ghiotto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanna","family":"Cutrona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cecilia","family":"Marini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianmario","family":"Sambuceti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franco","family":"Fais","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,1,27]]},"reference":[{"key":"3588_CR1","doi-asserted-by":"publisher","first-page":"790004","DOI":"10.3389\/fonc.2021.790004","volume":"11","author":"M Kwok","year":"2021","unstructured":"Kwok M, Wu CJ (2021) Clonal evolution of high-risk chronic lymphocytic leukemia: a contemporary perspective. Front Oncol 11:790004. https:\/\/doi.org\/10.3389\/fonc.2021.790004","journal-title":"Front Oncol"},{"key":"3588_CR2","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1182\/blood-2015-02-585059","volume":"126","author":"P Strati","year":"2015","unstructured":"Strati P, Shanafelt TD (2015) Monoclonal B-cell lymphocytosis and early-stage chronic lymphocytic leukemia: diagnosis, natural history, and risk stratification. Blood 126:454\u2013462. https:\/\/doi.org\/10.1182\/blood-2015-02-585059","journal-title":"Blood"},{"key":"3588_CR3","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/s41375-020-01057-5","volume":"35","author":"S Yang","year":"2021","unstructured":"Yang S, Varghese AM, Sood N, Chiattone C, Akinola NO, Huang X, Gale RP (2021) Ethnic and geographic diversity of chronic lymphocytic leukaemia. Leukemia 35:433\u2013439. https:\/\/doi.org\/10.1038\/s41375-020-01057-5","journal-title":"Leukemia"},{"key":"3588_CR4","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1093\/annonc\/mdw547","volume":"28","author":"R Stauder","year":"2017","unstructured":"Stauder R, Eichhorst B, Hamaker ME et al (2017) Management of chronic lymphocytic leukemia (CLL) in the elderly: a position paper from an international Society of Geriatric Oncology (SIOG) Task Force. Ann Oncol 28:218\u2013227. https:\/\/doi.org\/10.1093\/annonc\/mdw547","journal-title":"Ann Oncol"},{"key":"3588_CR5","doi-asserted-by":"publisher","first-page":"4814","DOI":"10.1158\/1078-0432.CCR-20-3993","volume":"27","author":"MJ Gordon","year":"2021","unstructured":"Gordon MJ, Kaempf A, Sitlinger A et al (2021) The chronic lymphocytic leukemia comorbidity index (CLL-CI): a three-factor comorbidity model. Clin Cancer Res 27:4814\u20134824. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-3993","journal-title":"Clin Cancer Res"},{"key":"3588_CR6","doi-asserted-by":"publisher","first-page":"14159","DOI":"10.1038\/s41598-017-12761-1","volume":"7","author":"C Marini","year":"2017","unstructured":"Marini C, Bruno S, Fiz F et al (2017) Functional activation of osteoclast commitment in chronic lymphocytic leukaemia: a possible role for RANK\/RANKL pathway. Sci Rep 7:14159. https:\/\/doi.org\/10.1038\/s41598-017-12761-1","journal-title":"Sci Rep"},{"key":"3588_CR7","doi-asserted-by":"publisher","first-page":"e488","DOI":"10.3324\/haematol.2016.148858","volume":"101","author":"AJ Olszewski","year":"2016","unstructured":"Olszewski AJ, Gutman R, Eaton CB (2016) Increased risk of axial fractures in patients with untreated chronic lymphocytic leukemia: a population-based analysis. Haematologica 101:e488\u2013e491. https:\/\/doi.org\/10.3324\/haematol.2016.148858","journal-title":"Haematologica"},{"key":"3588_CR8","doi-asserted-by":"publisher","first-page":"e24050","DOI":"10.1200\/JCO.2020.38.15_suppl.e24050","volume":"38","author":"D Brander","year":"2020","unstructured":"Brander D, Oeffinger K, Greiner M, Dinan M (2020) Prevalence, screening, treatment, and complications of osteoporosis and osteopenia in Medicare patients with chronic lymphocytic leukemia (CLL). J Clin Oncol 38:e24050. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.e24050","journal-title":"J Clin Oncol"},{"key":"3588_CR9","doi-asserted-by":"publisher","first-page":"A162","DOI":"10.1210\/jendso\/bvac150.333","volume":"6","author":"L Petty","year":"2022","unstructured":"Petty L, Stephens D, Sharma A (2022) ODP090 fragility fractures and osteoporosis screening in patients with chronic lymphocytic leukemia. J Endocr Soc 6:A162. https:\/\/doi.org\/10.1210\/jendso\/bvac150.333","journal-title":"J Endocr Soc"},{"key":"3588_CR10","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.bone.2011.03.774","volume":"49","author":"FH Ebetino","year":"2011","unstructured":"Ebetino FH, Hogan AM, Sun S et al (2011) The relationship between the chemistry and biological activity of the bisphosphonates. Bone 49:20\u201333. https:\/\/doi.org\/10.1016\/j.bone.2011.03.774","journal-title":"Bone"},{"key":"3588_CR11","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1359\/jbmr.1997.12.9.1358","volume":"12","author":"JC Frith","year":"1997","unstructured":"Frith JC, Monkkonen J, Blackburn GM, Russell RG, Rogers MJ (1997) Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5\u2019-(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro. J Bone Miner Res 12:1358\u20131367. https:\/\/doi.org\/10.1359\/jbmr.1997.12.9.1358","journal-title":"J Bone Miner Res"},{"key":"3588_CR12","doi-asserted-by":"publisher","first-page":"2803","DOI":"10.1111\/j.1582-4934.2009.00926.x","volume":"14","author":"M Coscia","year":"2010","unstructured":"Coscia M, Quaglino E, Iezzi M et al (2010) Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway. J Cell Mol Med 14:2803\u20132815. https:\/\/doi.org\/10.1111\/j.1582-4934.2009.00926.x","journal-title":"J Cell Mol Med"},{"key":"3588_CR13","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.bone.2010.07.016","volume":"48","author":"P Clezardin","year":"2011","unstructured":"Clezardin P (2011) Bisphosphonates\u2019 antitumor activity: an unravelled side of a multifaceted drug class. Bone 48:71\u201379. https:\/\/doi.org\/10.1016\/j.bone.2010.07.016","journal-title":"Bone"},{"key":"3588_CR14","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1038\/leu.2015.305","volume":"30","author":"BS Hanna","year":"2016","unstructured":"Hanna BS, McClanahan F, Yazdanparast H et al (2016) Depletion of CLL-associated patrolling monocytes and macrophages controls disease development and repairs immune dysfunction in vivo. Leukemia 30:570\u2013579. https:\/\/doi.org\/10.1038\/leu.2015.305","journal-title":"Leukemia"},{"key":"3588_CR15","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.3390\/ijms22031323","volume":"22","author":"M Weber","year":"2021","unstructured":"Weber M, Homm A, Muller S et al (2021) Zoledronate causes a systemic shift of macrophage polarization towards M1 in vivo. Int J Mol Sci 22:1323. https:\/\/doi.org\/10.3390\/ijms22031323","journal-title":"Int J Mol Sci"},{"key":"3588_CR16","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.4049\/jimmunol.1002514","volume":"187","author":"B Castella","year":"2011","unstructured":"Castella B, Riganti C, Fiore F et al (2011) Immune modulation by zoledronic acid in human myeloma: an advantageous cross-talk between Vgamma9Vdelta2 T cells, alphabeta CD8+ T cells, regulatory T cells, and dendritic cells. J Immunol 187:1578\u20131590. https:\/\/doi.org\/10.4049\/jimmunol.1002514","journal-title":"J Immunol"},{"key":"3588_CR17","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s00280-008-0710-1","volume":"62","author":"KL Silva","year":"2008","unstructured":"Silva KL, Vasconcellos DV, Castro ED, Vasconcelos FC, Bigni R, Maia RC (2008) Bisphosphonates induce apoptosis in CLL cells independently of MDR phenotype. Cancer Chemother Pharmacol 62:165\u2013171. https:\/\/doi.org\/10.1007\/s00280-008-0710-1","journal-title":"Cancer Chemother Pharmacol"},{"key":"3588_CR18","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1111\/bcp.13867","volume":"85","author":"S Cremers","year":"2019","unstructured":"Cremers S, Drake MT, Ebetino FH, Bilezikian JP, Russell RGG (2019) Pharmacology of bisphosphonates. Br J Clin Pharmacol 85:1052\u20131062. https:\/\/doi.org\/10.1111\/bcp.13867","journal-title":"Br J Clin Pharmacol"},{"key":"3588_CR19","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.2119\/molmed.2011.00360","volume":"17","author":"C Calissano","year":"2011","unstructured":"Calissano C, Damle RN, Marsilio S et al (2011) Intraclonal complexity in chronic lymphocytic leukemia: fractions enriched in recently born\/divided and older\/quiescent cells. Mol Med 17:1374\u20131382. https:\/\/doi.org\/10.2119\/molmed.2011.00360","journal-title":"Mol Med"},{"key":"3588_CR20","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1038\/leu.2017.11","volume":"31","author":"TM Herndon","year":"2017","unstructured":"Herndon TM, Chen SS, Saba NS et al (2017) Direct in vivo evidence for increased proliferation of CLL cells in lymph nodes compared to bone marrow and peripheral blood. Leukemia 31:1340\u20131347. https:\/\/doi.org\/10.1038\/leu.2017.11","journal-title":"Leukemia"},{"key":"3588_CR21","doi-asserted-by":"publisher","DOI":"10.1172\/JCI149308","author":"AN Mazzarello","year":"2022","unstructured":"Mazzarello AN, Gentner-Gobel E, Duhren-von Minden M et al (2022) B cell receptor isotypes differentially associate with cell signaling, kinetics, and outcome in chronic lymphocytic leukemia. J Clin Invest. https:\/\/doi.org\/10.1172\/JCI149308","journal-title":"J Clin Invest"},{"key":"3588_CR22","doi-asserted-by":"publisher","first-page":"3211","DOI":"10.4161\/cc.7.20.6830","volume":"7","author":"R Ponassi","year":"2008","unstructured":"Ponassi R, Biasotti B, Tomati V et al (2008) A novel Bim-BH3-derived Bcl-XL inhibitor: biochemical characterization, in vitro, in vivo and ex-vivo anti-leukemic activity. Cell Cycle 7:3211\u20133224. https:\/\/doi.org\/10.4161\/cc.7.20.6830","journal-title":"Cell Cycle"},{"key":"3588_CR23","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1002\/cyto.990130508","volume":"13","author":"S Bruno","year":"1992","unstructured":"Bruno S, Gorczyca W, Darzynkiewicz Z (1992) Effect of ionic strength in immunocytochemical detection of the proliferation associated nuclear antigens p120, PCNA, and the protein reacting with Ki-67 antibody. Cytometry 13:496\u2013501. https:\/\/doi.org\/10.1002\/cyto.990130508","journal-title":"Cytometry"},{"key":"3588_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/antiox12010043","author":"C Marini","year":"2022","unstructured":"Marini C, Cossu V, Carta S et al (2022) Fundamental role of pentose phosphate pathway within the endoplasmic reticulum in glutamine addiction of triple-negative breast cancer cells. Antioxidants (Basel). https:\/\/doi.org\/10.3390\/antiox12010043","journal-title":"Antioxidants (Basel)"},{"key":"3588_CR25","doi-asserted-by":"publisher","first-page":"263","DOI":"10.4161\/cbt.8.3.7424","volume":"8","author":"F Ghiotto","year":"2009","unstructured":"Ghiotto F, Fais F, Tenca C et al (2009) Apoptosis of B-cell chronic lymphocytic leukemia cells induced by a novel BH3 peptidomimetic. Cancer Biol Ther 8:263\u2013271. https:\/\/doi.org\/10.4161\/cbt.8.3.7424","journal-title":"Cancer Biol Ther"},{"key":"3588_CR26","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1073\/pnas.1424741112","volume":"112","author":"S Carta","year":"2015","unstructured":"Carta S, Penco F, Lavieri R, Martini A, Dinarello CA, Gattorno M, Rubartelli A (2015) Cell stress increases ATP release in NLRP3 inflammasome-mediated autoinflammatory diseases, resulting in cytokine imbalance. Proc Natl Acad Sci USA 112:2835\u20132840. https:\/\/doi.org\/10.1073\/pnas.1424741112","journal-title":"Proc Natl Acad Sci USA"},{"key":"3588_CR27","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/s41598-018-36853-8","volume":"9","author":"C Schleiss","year":"2019","unstructured":"Schleiss C, Ilias W, Tahar O et al (2019) BCR-associated factors driving chronic lymphocytic leukemia cells proliferation ex vivo. Sci Rep 9:701. https:\/\/doi.org\/10.1038\/s41598-018-36853-8","journal-title":"Sci Rep"},{"key":"3588_CR28","doi-asserted-by":"publisher","first-page":"279","DOI":"10.3324\/haematol.2011.052829","volume":"97","author":"G Del Poeta","year":"2012","unstructured":"Del Poeta G, Del Principe MI, Zucchetto A et al (2012) CD69 is independently prognostic in chronic lymphocytic leukemia: a comprehensive clinical and biological profiling study. Haematologica 97:279\u2013287. https:\/\/doi.org\/10.3324\/haematol.2011.052829","journal-title":"Haematologica"},{"key":"3588_CR29","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1111\/j.1365-2141.2007.06965.x","volume":"140","author":"TD Shanafelt","year":"2008","unstructured":"Shanafelt TD, Geyer SM, Bone ND et al (2008) CD49d expression is an independent predictor of overall survival in patients with chronic lymphocytic leukaemia: a prognostic parameter with therapeutic potential. Br J Haematol 140:537\u2013546. https:\/\/doi.org\/10.1111\/j.1365-2141.2007.06965.x","journal-title":"Br J Haematol"},{"key":"3588_CR30","doi-asserted-by":"publisher","first-page":"52225","DOI":"10.18632\/oncotarget.13660","volume":"8","author":"F Boissard","year":"2017","unstructured":"Boissard F, Tosolini M, Ligat L, Quillet-Mary A, Lopez F, Fournie JJ, Ysebaert L, Poupot M (2017) Nurse-like cells promote CLL survival through LFA-3\/CD2 interactions. Oncotarget 8:52225\u201352236. https:\/\/doi.org\/10.18632\/oncotarget.13660","journal-title":"Oncotarget"},{"key":"3588_CR31","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1002\/cncr.31931","volume":"125","author":"S Sharma","year":"2019","unstructured":"Sharma S, Rai KR (2019) Chronic lymphocytic leukemia (CLL) treatment: So many choices, such great options. Cancer 125:1432\u20131440. https:\/\/doi.org\/10.1002\/cncr.31931","journal-title":"Cancer"},{"key":"3588_CR32","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1056\/NEJMoa2213093","volume":"388","author":"B Eichhorst","year":"2023","unstructured":"Eichhorst B, Niemann CU, Kater AP et al (2023) First-line venetoclax combinations in chronic lymphocytic leukemia. N Engl J Med 388:1739\u20131754. https:\/\/doi.org\/10.1056\/NEJMoa2213093","journal-title":"N Engl J Med"},{"key":"3588_CR33","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.bone.2006.03.011","volume":"39","author":"M Romanello","year":"2006","unstructured":"Romanello M, Bivi N, Pines A, Deganuto M, Quadrifoglio F, Moro L, Tell G (2006) Bisphosphonates activate nucleotide receptors signaling and induce the expression of Hsp90 in osteoblast-like cell lines. Bone 39:739\u2013753. https:\/\/doi.org\/10.1016\/j.bone.2006.03.011","journal-title":"Bone"},{"key":"3588_CR34","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s00784-010-0477-8","volume":"16","author":"FP Koch","year":"2012","unstructured":"Koch FP, Merkel C, Ziebart T, Smeets R, Walter C, Al-Nawas B (2012) Influence of bisphosphonates on the osteoblast RANKL and OPG gene expression in vitro. Clin Oral Investig 16:79\u201386. https:\/\/doi.org\/10.1007\/s00784-010-0477-8","journal-title":"Clin Oral Investig"},{"key":"3588_CR35","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1002\/jcp.20547","volume":"207","author":"P Secchiero","year":"2006","unstructured":"Secchiero P, Corallini F, Barbarotto E, Melloni E, di Iasio MG, Tiribelli M, Zauli G (2006) Role of the RANKL\/RANK system in the induction of interleukin-8 (IL-8) in B chronic lymphocytic leukemia (B-CLL) cells. J Cell Physiol 207:158\u2013164. https:\/\/doi.org\/10.1002\/jcp.20547","journal-title":"J Cell Physiol"},{"key":"3588_CR36","doi-asserted-by":"publisher","first-page":"4382","DOI":"10.1182\/blood.V87.10.4382.bloodjournal87104382","volume":"87","author":"P Francia di Celle","year":"1996","unstructured":"Francia di Celle P, Mariani S, Riera L, Stacchini A, Reato G, Foa R (1996) Interleukin-8 induces the accumulation of B-cell chronic lymphocytic leukemia cells by prolonging survival in an autocrine fashion. Blood 87:4382\u20134389","journal-title":"Blood"},{"key":"3588_CR37","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1172\/JCI6800","volume":"104","author":"LI Plotkin","year":"1999","unstructured":"Plotkin LI, Weinstein RS, Parfitt AM, Roberson PK, Manolagas SC, Bellido T (1999) Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest 104:1363\u20131374. https:\/\/doi.org\/10.1172\/JCI6800","journal-title":"J Clin Invest"},{"key":"3588_CR38","doi-asserted-by":"publisher","first-page":"33206","DOI":"10.1074\/jbc.274.47.33206","volume":"274","author":"OR Baricordi","year":"1999","unstructured":"Baricordi OR, Melchiorri L, Adinolfi E, Falzoni S, Chiozzi P, Buell G, Di Virgilio F (1999) Increased proliferation rate of lymphoid cells transfected with the P2X(7) ATP receptor. J Biol Chem 274:33206\u201333208. https:\/\/doi.org\/10.1074\/jbc.274.47.33206","journal-title":"J Biol Chem"},{"key":"3588_CR39","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1182\/blood.v99.2.706","volume":"99","author":"E Adinolfi","year":"2002","unstructured":"Adinolfi E, Melchiorri L, Falzoni S et al (2002) P2X7 receptor expression in evolutive and indolent forms of chronic B lymphocytic leukemia. Blood 99:706\u2013708. https:\/\/doi.org\/10.1182\/blood.v99.2.706","journal-title":"Blood"},{"key":"3588_CR40","doi-asserted-by":"publisher","first-page":"6141","DOI":"10.1182\/blood-2011-08-374728","volume":"118","author":"S Serra","year":"2011","unstructured":"Serra S, Horenstein AL, Vaisitti T et al (2011) CD73-generated extracellular adenosine in chronic lymphocytic leukemia creates local conditions counteracting drug-induced cell death. Blood 118:6141\u20136152. https:\/\/doi.org\/10.1182\/blood-2011-08-374728","journal-title":"Blood"},{"key":"3588_CR41","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/sj.pcan.4500705","volume":"7","author":"JP Coxon","year":"2004","unstructured":"Coxon JP, Oades GM, Colston KW, Kirby RS (2004) Advances in the use of bisphosphonates in the prostate cancer setting. Prostate Cancer Prostatic Dis 7:99\u2013104. https:\/\/doi.org\/10.1038\/sj.pcan.4500705","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"3588_CR42","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1038\/sj.leu.2400892","volume":"12","author":"A Aparicio","year":"1998","unstructured":"Aparicio A, Gardner A, Tu Y, Savage A, Berenson J, Lichtenstein A (1998) In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates. Leukemia 12:220\u2013229. https:\/\/doi.org\/10.1038\/sj.leu.2400892","journal-title":"Leukemia"},{"key":"3588_CR43","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/BF02983531","volume":"79","author":"S Kimura","year":"2004","unstructured":"Kimura S, Kuroda J, Segawa H, Sato K, Nogawa M, Yuasa T, Ottmann OG, Maekawa T (2004) Antiproliferative efficacy of the third-generation bisphosphonate, zoledronic acid, combined with other anticancer drugs in leukemic cell lines. Int J Hematol 79:37\u201343. https:\/\/doi.org\/10.1007\/BF02983531","journal-title":"Int J Hematol"},{"key":"3588_CR44","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.celrep.2013.09.004","volume":"5","author":"E Tonti","year":"2013","unstructured":"Tonti E, Jimenez de Oya N, Galliverti G et al (2013) Bisphosphonates target B cells to enhance humoral immune responses. Cell Rep 5:323\u2013330. https:\/\/doi.org\/10.1016\/j.celrep.2013.09.004","journal-title":"Cell Rep"},{"key":"3588_CR45","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1471-2385-1-2","volume":"1","author":"E Savio","year":"2001","unstructured":"Savio E, Gaudiano J, Robles AM et al (2001) Re-HEDP\u202f: pharmacokinetic characterization, clinical and dosimetric evaluation in osseous metastatic patients with two levels of radiopharmaceutical dose. BMC Nucl Med 1:2. https:\/\/doi.org\/10.1186\/1471-2385-1-2","journal-title":"BMC Nucl Med"},{"key":"3588_CR46","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1177\/009127002762491316","volume":"42","author":"T Chen","year":"2002","unstructured":"Chen T, Berenson J, Vescio R et al (2002) Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol 42:1228\u20131236. https:\/\/doi.org\/10.1177\/009127002762491316","journal-title":"J Clin Pharmacol"},{"key":"3588_CR47","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1124\/dmd.108.021071","volume":"36","author":"HM Weiss","year":"2008","unstructured":"Weiss HM, Pfaar U, Schweitzer A, Wiegand H, Skerjanec A, Schran H (2008) Biodistribution and plasma protein binding of zoledronic acid. Drug Metab Dispos 36:2043\u20132049. https:\/\/doi.org\/10.1124\/dmd.108.021071","journal-title":"Drug Metab Dispos"},{"key":"3588_CR48","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/s8756-3282(02)00841-4","volume":"31","author":"K Villikka","year":"2002","unstructured":"Villikka K, Perttunen K, Rosnell J, Ikavalko H, Vaho H, Pylkkanen L (2002) The absolute bioavailability of clodronate from two different oral doses. Bone 31:418\u2013421. https:\/\/doi.org\/10.1016\/s8756-3282(02)00841-4","journal-title":"Bone"},{"key":"3588_CR49","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1172\/JCI115539","volume":"88","author":"M Sato","year":"1991","unstructured":"Sato M, Grasser W, Endo N, Akins R, Simmons H, Thompson DD, Golub E, Rodan GA (1991) Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 88:2095\u20132105. https:\/\/doi.org\/10.1172\/JCI115539","journal-title":"J Clin Invest"},{"key":"3588_CR50","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/8756-3282(95)00445-9","volume":"18","author":"JH Lin","year":"1996","unstructured":"Lin JH (1996) Bisphosphonates: a review of their pharmacokinetic properties. Bone 18:75\u201385. https:\/\/doi.org\/10.1016\/8756-3282(95)00445-9","journal-title":"Bone"},{"key":"3588_CR51","doi-asserted-by":"publisher","first-page":"551","DOI":"10.2165\/00003088-200544060-00001","volume":"44","author":"SC Cremers","year":"2005","unstructured":"Cremers SC, Pillai G, Papapoulos SE (2005) Pharmacokinetics\/pharmacodynamics of bisphosphonates: use for optimisation of intermittent therapy for osteoporosis. Clin Pharmacokinet 44:551\u2013570. https:\/\/doi.org\/10.2165\/00003088-200544060-00001","journal-title":"Clin Pharmacokinet"},{"key":"3588_CR52","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1177\/0091270002239824","volume":"43","author":"A Skerjanec","year":"2003","unstructured":"Skerjanec A, Berenson J, Hsu C, Major P, Miller WH Jr, Ravera C, Schran H, Seaman J, Waldmeier F (2003) The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function. J Clin Pharmacol 43:154\u2013162. https:\/\/doi.org\/10.1177\/0091270002239824","journal-title":"J Clin Pharmacol"},{"key":"3588_CR53","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/s13054-020-02915-5","volume":"24","author":"M Schulz","year":"2020","unstructured":"Schulz M, Schmoldt A, Andresen-Streichert H, Iwersen-Bergmann S (2020) Revisited: therapeutic and toxic blood concentrations of more than 1100 drugs and other xenobiotics. Crit Care 24:195. https:\/\/doi.org\/10.1186\/s13054-020-02915-5","journal-title":"Crit Care"},{"key":"3588_CR54","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1023\/a:1011024200280","volume":"18","author":"DY Mitchell","year":"2001","unstructured":"Mitchell DY, Barr WH, Eusebio RA, Stevens KA, Duke FP, Russell DA, Nesbitt JD, Powell JH, Thompson GA (2001) Risedronate pharmacokinetics and intra- and inter-subject variability upon single-dose intravenous and oral administration. Pharm Res 18:166\u2013170. https:\/\/doi.org\/10.1023\/a:1011024200280","journal-title":"Pharm Res"},{"key":"3588_CR55","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1007\/s00228-001-0411-8","volume":"57","author":"S Cremers","year":"2002","unstructured":"Cremers S et al (2002) A pharmacokinetic and pharmacodynamic model for intravenous bisphosphonate (pamidronate) in osteoporosis. Eur J Clin Pharmacol 57:883\u2013890. https:\/\/doi.org\/10.1007\/s00228-001-0411-8","journal-title":"Eur J Clin Pharmacol"},{"key":"3588_CR56","doi-asserted-by":"publisher","first-page":"592205","DOI":"10.3389\/fonc.2020.592205","volume":"10","author":"MV Haselager","year":"2020","unstructured":"Haselager MV, Kater AP, Eldering E (2020) Proliferative signals in chronic lymphocytic leukemia; what are we missing? Front Oncol 10:592205. https:\/\/doi.org\/10.3389\/fonc.2020.592205","journal-title":"Front Oncol"},{"key":"3588_CR57","doi-asserted-by":"publisher","first-page":"e119","DOI":"10.1016\/S1470-2045(20)30559-3","volume":"22","author":"E Terpos","year":"2021","unstructured":"Terpos E, Zamagni E, Lentzsch S et al (2021) Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group. Lancet Oncol 22:e119\u2013e130. https:\/\/doi.org\/10.1016\/S1470-2045(20)30559-3","journal-title":"Lancet Oncol"},{"key":"3588_CR58","doi-asserted-by":"publisher","first-page":"100470","DOI":"10.1016\/j.jbo.2023.100470","volume":"39","author":"JP Lorange","year":"2023","unstructured":"Lorange JP, Ramirez Garcia Luna J, Grou-Boileau F, Rosenzweig D, Weber MH, Akoury E (2023) Management of bone metastasis with zoledronic acid: a systematic review and Bayesian network meta-analysis. J Bone Oncol 39:100470. https:\/\/doi.org\/10.1016\/j.jbo.2023.100470","journal-title":"J Bone Oncol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-023-03588-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-023-03588-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-023-03588-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,24]],"date-time":"2024-02-24T08:06:18Z","timestamp":1708761978000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-023-03588-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,27]]},"references-count":58,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,2]]}},"alternative-id":["3588"],"URL":"https:\/\/doi.org\/10.1007\/s00262-023-03588-z","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,27]]},"assertion":[{"value":"1 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. All samples were obtained from patients enrolled in the observational multicenter study (clinical trial.gov identifier NCT00917540).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All donors signed an informed consent according to the Declaration of Helsinki.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}],"article-number":"27"}}